Figure 4.

Actionable alterations alongside progression-free survival for molecularly matched and unmatched therapies given as second-line therapy (A) or as later lines of therapy (B)

Swimmer plot highlighting examples of specific regimens documented in patients with actionable alterations. Reasons for discontinuing therapy are shown in the key. This figure provides examples of actual therapies that were selected in patients with actionable mutations. All 38 patients who received a matched therapy in the second line or later are represented here. All patients who only received unmatched therapies in second line and later after receipt of the Perthera report are represented here. Patients were represented only once in either part A or B, with the exception of five patients. CAPEOX=capecitabine and oxaliplatin. FOLFIRI=flurouracil and irinotecan. FOLFIRINOX=fluorouracil, irinotecan, and oxaliplatin. FOLFOX=fluorouracil and oxaliplatin. IMRT=intensity-modulated radiotherapy. MSI-H=high microsatellite instability. nab=nanoparticle albumin-bound. *Five patients represented in both parts A and B. †Only one line of therapy per patient is represented, with the best outcome represented. If a patient rapidly progressed on their third line of therapy but had a more durable response while on their fourth line of therapy, progression-free survival for the fourth line of therapy was presented for that patient in the swimmers plot instead (for both the matched and unmatched groups).